|
BIA
Separations is an ISO 9001:2000 Certified Company.
 |
| NEWS |
|
| A
Royal Visit to BIA Separations |
| |
Prince William
and Princess Maxima of the Royal Kingdom of the Netherlands were
recently hosted by BIA Separations during an official Royal visit
to Slovenia. BIA Separations was selected for the visit because it
is an example of a company that provides an innovative product to
the world’s biopharmaceutical marketplace and allows young scientists
and support staff to participate in the research and production of
products and services that impacts this rapidly growing market segment.
The Royal Couple were able to see first hand the laboratories and meet
the talented teams that specialize in liquid chromatographic methods
and developing monolithic materials for the next century. |
|
|
| New
Company Headquarters |
| |
In July 2007,
BIA Separations Slovenia became a wholly owned subsidiary of
BIA Separations GesmbH Austria. BIA Separations GesmbH Austria was
established by a group of international investors with the aim of
providing novel and cutting edge technologies for the analysis,
separation and purification of drug substances and molecules for
therapeutic/diagnostic use. To pursue this goal, the company first
needed to acquire the “monolith technology” of BIA Separations
Slovenia by purchasing 100% of its shares. BIA Separations Austria is
committed to continued development of monolith technology to ensure
that the biotechnology industry can implement more efficient
technologies for the analysis and purification of plasmid DNA,
virus particles, and proteins.
If you are interested in joining this growing and dynamic company,
please see our Careers Section. |
|
|
| BIA
Separations successfully defends its IP Position |
| |
On 28 June 2007,
there was a hearing at the European Patent Office which confirmed
the revocation of European Patent EP 0 765 183 B1 owned by GE Healthcare.
The claimed subject matter was providing a gap between a sample distributor
and a monolithic separation medium. The Board of Appeal shared the view of
the Opposition Division which held that the technology covered by
EP 0 765 183 B1 was anticipated by the prior art, however, came to
this conclusion based on written publications rather than prior public use
as the Opposition Division held. |
|
|
| Clinical
Phase I study of new Flu Vaccine launched |
| |
Avir
Green Hills Biotechnology (GHB) announced the
start of the clinical phase I study for their
novel influenza vaccine “Envax” which provides
coverage against a wider range of influenza virus
variants than is generally possible with conventional
vaccines. BIA Separations is a key member of
the consortium that helped bring this innovative
vaccine to this first step in the drug approval
process. |
|
|
|
New
article on CIM®: Keep up to date with the latest research and
applications of CIM® monolithic columns. |
| |
Purification and concentration of bacteriophage T4
using monolithic chromatographic supports.
J Chromatogr B Analyt Technol Biomed Life Sci.
2007, Jun 7. (Abstract)
Influence of the methacrylate monolith structure on
genomic DNA mechanical degradation, enzymes activity
and clogging.
J Chromatogr A, 2007,1160, 176-83.
(Abstract)
Pseudoaffinity Chromatography Using a Convective
Interaction Media® Disk Monolithic Column.
Chromatographia. 2007, 65, 639-648. (Abstract)
|
|
|
|
|
PAST
HIGHLIGHTS
|
|
| CIM®
highlighted in BioProcess International |
| |
CIM® is recognized as a preparative and process
technology for BioIndustrial Chromatography
on page 10 of the BioProcess International
May Supplement focusing on Bioindustrial
Chromatography. Read
More. Reprinted with
permission from BioProcess
International. |
|
|
| Monoliths
reduce residence time to seconds with protein A affinity |
| |
Pete Gagnon,
Validated Biosystems, demonstrated this fact in a presentation
entitled "The Protein A Paradigm: Can it be improved? Can it be
replaced?" at IBC's 18th International Conference on Production
and Manufacturing of Monoclonal Antibodies, Carlsbad California,
Feb. 28 - Mar 2, 2007. You can download a pdf copy and learn how
to improve your productivity today. |
|
|
| Pegylated
proteins application |
| |
Pfizer scientist,
Dr. Troii Hall demonstrates the superiority of CIM® Monolithic Columns
for the purification of Pegylated Proteins over other columns.
Read his article now! |
|
|
| Plasmid
DNA process awarded the Frost & Sullivan
Technology award |
| |
Boehringer
Ingelheim Austria GmbH has received the 2004
Frost & Sullivan Technology Leadership
Award for their innovative pDNA manufacturing
process developed in collaboration with BIA
Separations. The award was justified with
the following words (among other): "The
company is leading technology providers in
the race to capitalise on the huge demand
for new therapeutics by investing in an area
which has received scant attention - technology
innovation in downstream processing." The
key to the pDNA downstream processing are
our propritary CIM® monolithic column platform
technology that is optimized for biochromatographic
applications. |
|
|
| Proceedings
of the 2004 and 2006 Monolith Summer School |
| |
2006: Journal of Chromatography A Volume 1144, Issue 1, pages 1-160
2004: Journal of Chromatography A Volume 1065, Issue 1, pages 1-144 |
|
|
| Company
Milestones |
| |
| 2006 |
CIM®
QA Monolithic Supports receive Drug Master File Number (19695) |
| 2004 |
5th
Anniversary of BIA Separations |
| 2003 |
ISO
9001:2000 Certification (Q-579) |
| 2002 |
CIM®
DEAE Monolithic Supports receive Drug Master File Number (15838)
Analytical Lab Passes FDA Inspection |
| 2001 |
BIA Separations and Boehringer Ingelheim announce
cooperation in pDNA Manufacturing |
| 1998 |
BIA
Separations Founded |
|
|
|
|
|
|
|
NEW
PRODUCTS
|
|
|
|
NEW
APPLICATIONS
|
|
|
|
NEXT
EVENTS
|
|
| |
| BioProcess International, Vienna, 2008
April 21 – 24, 2008
Vienna, Austria
|
| |
| Seminar: Monolithic Technology Platform for the Purification of Large Biomolecules
University of Florida ICBR (Interdisciplinary Center for Biotechnology Research)
April 25, 2008
Florida, USA
Tony Brazzale, Eastern US Regional Manager from Bia Separantions will have a series of presentations on the monolithic technology platforms optimized for purification of large biomolecules. Topics will include purification of viruses, phages, antibodies, vaccines and the use of monoliths for bioconversion.
|
| |
| Monolith
Summerschool and Symposium
May
30-June 4, 2008
Portorož, Slovenia
|
| |
| WilBio Viral Vectors and Vaccines 2008
October 20 – 22, 2008
Houston, Texas
|
| |
| BioProcess International, CA, 2008
November 13 - 16
Anaheim, CA
|
 |
|
|
